Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen
COVIDOLIP
1 other identifier
observational
62
1 country
1
Brief Summary
SARS-COV 2 infection might be responsible for sever pneumonia. Obesity seems to be a risk factor for severe SARS-COV 2 pneumonia. Lipid metabolism alteration are described with both obesity and sepsis. The aim of the present study was to describe association between lipid metabolism, obesity, sepsis inflammation and clinical outcome in COVID-19 patient with severe pneumonia compared with severe pneumonia caused by other pathogenes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 7, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 7, 2020
CompletedFirst Submitted
Initial submission to the registry
June 16, 2020
CompletedFirst Posted
Study publicly available on registry
June 17, 2020
CompletedFebruary 2, 2026
January 1, 2026
1 month
June 16, 2020
January 29, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Cholesterol concentration
Within 48 hours following hospital admission
Secondary Outcomes (1)
LDL cholesterol / HDL cholesterol/ Lipoprotein size and composition/ Non esterified Fatty acid/ Triglyceridemia/ CETP and PLTP activity/ apolipoprotein canceration/ lipid peroxidation/ Pro and anti inflammatory profile.
Within 48 hours following hospital admission
Study Arms (2)
COVID-19 severe pneumonia
Severe pneumonia due to other pathogene
Interventions
bioassays carried out on samples already collected and conserved
Eligibility Criteria
patient with pneumopathy
You may qualify if:
- of the following criteria: Cough/ Dyspnea/ Spitting/ Thoracic pain/ Hyperthermia (\>=38 °C) Hypothermia (\< 35°C) AND new radiologic pulmonary infiltrate
- At admission or within 48 hours following hospital admission
- With 2 qSOFA criteria: MAP =\< 100 mmHg, Respiratory Rate \>= 22, Glasgow score \< 15 OR on mechanical ventilation OR under vasopressor
- Age \> 18
- affiliated to social security
You may not qualify if:
- Pregnancy
- immunodepression
- Pathology known to cause severe lymphopenia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chu Dijon Bourgogne
Dijon, 21000, France
Related Publications (1)
Nguyen M, Bourredjem A, Piroth L, Bouhemad B, Jalil A, Pallot G, Le Guern N, Thomas C, Pilot T, Bergas V, Choubley H, Quenot JP, Charles PE, Lagrost L, Deckert V, de Barros JP, Guinot PG, Masson D, Binquet C, Gautier T, Blot M; Lymphonie study group. High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia. Sci Rep. 2021 May 24;11(1):10824. doi: 10.1038/s41598-021-90362-9.
PMID: 34031519RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 16, 2020
First Posted
June 17, 2020
Study Start
April 7, 2020
Primary Completion
May 7, 2020
Study Completion
May 7, 2020
Last Updated
February 2, 2026
Record last verified: 2026-01